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Comparison of treatment effects between animal experiments and
clinical trials: systematic review
Pablo Perel, Ian Roberts, Emily Sena, Philipa Wheble, Catherine Briscoe, Peter Sandercock, Malcolm Macleod,
Luciano E Mignini, Pradeep Jayaram, Khalid S Khan
Abstract
Objective To examine concordance between treatment effects
in animal experiments and clinical trials.
Study design Systematic review.
Data sourcesMedline, Embase, SIGLE, NTIS, Science Citation
Index, CAB, BIOSIS.
Study selection Animal studies for interventions with
unambiguous evidence of a treatment effect (benefit or harm)
in clinical trials: head injury, antifibrinolytics in haemorrhage,
thrombolysis in acute ischaemic stroke, tirilazad in acute
ischaemic stroke, antenatal corticosteroids to prevent neonatal
respiratory distress syndrome, and bisphosphonates to treat
osteoporosis.
Review methods Data were extracted on study design,
allocation concealment, number of randomised animals, type of
model, intervention, and outcome.
Results Corticosteroids did not show any benefit in clinical
trials of treatment for head injury but did show a benefit in
animal models (pooled odds ratio for adverse functional
outcome 0.58, 95% confidence interval 0.41 to 0.83).
Antifibrinolytics reduced bleeding in clinical trials but the data
were inconclusive in animal models. Thrombolysis improved
outcome in patients with ischaemic stroke. In animal models,
tissue plasminogen activator reduced infarct volume by 24%
(95% confidence interval 20% to 28%) and improved
neurobehavioural scores by 23% (17% to 29%). Tirilazad was
associated with a worse outcome in patients with ischaemic
stroke. In animal models, tirilazad reduced infarct volume by
29% (21% to 37%) and improved neurobehavioural scores by
48% (29% to 67%). Antenatal corticosteroids reduced
respiratory distress and mortality in neonates whereas in
animal models respiratory distress was reduced but the effect
on mortality was inconclusive (odds ratio 4.2, 95% confidence
interval 0.85 to 20.9). Bisphosphonates increased bone mineral
density in patients with osteoporosis. In animal models the
bisphosphonate alendronate increased bone mineral density
compared with placebo by 11.0% (95% confidence interval
9.2% to 12.9%) in the combined results for the hip region. The
corresponding treatment effect in the lumbar spine was 8.5%
(5.8% to 11.2%) and in the combined results for the forearms
(baboons only) was 1.7% ( − 1.4% to 4.7%).
Conclusions Discordance between animal and human studies
may be due to bias or to the failure of animal models to mimic
clinical disease adequately.
Introduction
Before clinical trials are carried out, the safety and effectiveness
of new drugs are usually tested in animal models.1 Although the
use of animals in medical research is controversial, a poll by the
Medical Research Council found that most people support their
use provided that there are benefits to human health care, no
alternative exists, and no unnecessary suffering occurs.2
The usefulness of animal testing has, however, been
questioned.3–5 Some believe that the results from animal experi-
ments cannot be applied to humans because of the biological
differences between the species and because the results of animal
experiments often depend on the type of animal model.3 To date
the methods used to assess the value of animal trials include his-
torical analyses, critiques of animal models, surveys of clinicians,
and citation analyses. In this paper we compared treatment
effects from systematic reviews of clinical trials with those of our
own systematic review of the corresponding animal
experiments.6–8
Methods
We identified six interventions for which there was evidence of a
treatment effect (benefit or harm) in systematic reviews of clini-
cal trials and we carried out a systematic review of the
corresponding animal experiments. We searched for all
published and unpublished controlled studies in animal models
for the following interventions: corticosteroids in traumatic head
injury,9–11 antifibrinolytics in haemorrhage,12 thrombolysis in
acute ischaemic stroke,13 14 tirilazad in acute ischaemic stroke,15
antenatal corticosteroids to prevent neonatal respiratory distress
syndrome,16 and bisphosphonates to prevent and treat
osteoporosis.17 We were unaware of the results of the animal
studies when selecting the six interventions. We carried out our
systematic review in accordance with the recommended
methods for health technology assessment, described
elsewhere.18–21 Briefly, we systematically searched for randomised
and non-randomised controlled studies of the six interventions
in animal models. To be eligible for inclusion the studies had to
report outcomes corresponding to those for which a treatment
effect had been shown in clinical trials.
We searched Medline, Embase, SIGLE (System for Informa-
tion on Grey Literature), NTIS (National Technical Information
Service), Science Citation Index, CAB, and BIOSIS. Details of the
search strategies are presented elsewhere.18 Reference lists were
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checked and we contacted the authors of included studies,
relevant drug companies, and the authorities that regulate
animal testing—the Home Office in the United Kingdom. No
language restrictions were applied. To reduce the number of
missed studies two reviewers examined the results for potentially
relevant interventions.22 These reports were retrieved in full. Two
reviewers independently applied the selection criteria.
Eligible reports were assessed for methodological quality.23
Two reviewers extracted data on allocation concealment and
blinding. If the method of allocation concealment was not clearly
reported, we tried to contact the authors for clarification. We
used Schulz et al’s definition for adequate concealment.24 Two
reviewers extracted data on study design, allocation conceal-
ment, number of randomised animals, type of model,
intervention, outcome, and funding source. We contacted
authors if relevant outcome measures were not reported but we
believed the data to be available. The reviewers were not blinded
to the authors or journal.25
For dichotomous measures (for example, mortality) we
estimated odds ratios and confidence intervals and for continu-
ous measures (for example, infarct volume) we estimated the
effect size:
Effect size = ((outcome[control] − outcome[treated]) / out-
come[control]) × 100%
We calculated pooled odds ratios, effect sizes, and 95% confi-
dence intervals using a random effects model. Heterogeneity was
examined using the I2 statistic.26 We investigated the possibility of
small study bias by checking for funnel plot asymmetry and by
using graphical and statistical methods.27
Results
Corticosteroids for traumatic head injury
Clinical trials of corticosteroids for traumatic head injury did not
show any benefit and showed an increased risk of mortality.9
Seventeen reports were found in animal models of traumatic
head injury (19 comparisons).w1-w17 The quality of the
experiments was poor (table 1). Only three reports (four
comparisons) reported adequate allocation concealment. Two
experiments reported the effect of corticosteroids on mortality.
An effect estimate could not be calculated for one of these
experiments because the number of animals in each group was
not stated and in the other all the animals died.
Seven experiments reported neurological outcomes. Neuro-
logical status was assessed by the grip test and neurological
severity score. The grip test measures how long (up to a
maximum of 30 seconds) a mouse remains on a taut string sus-
pended between two metal bars. Animals were considered
“severely disabled” if they held on for less than five seconds. Four
experiments reported the grip test: pooled odds ratio 0.58 (95%
confidence interval 0.41 to 0.83; fig 1). No heterogeneity was
found (I_= 0%). Neurological severity score was used to assess
the clinical condition of rats after trauma and was based on a
series of tests. High scores indicated a worse outcome. Three
experiments reported the neurological severity score but none
reported the scores in each group, stating instead that there was
“no significant difference.”
Antifibrinolytics in haemorrhage
Clinical trials show that antifibrinolytics reduce blood loss
during surgery.12 Eight reports were found on the effects of anti-
fibrinolytics in animal models (eight comparisons).w18-w25 The
quality of the experiments was poor (table 1). One did not give
the number of animals. One reported mortality, five reported
bleeding time, five reported blood loss, and one reported
haemoglobin loss. None reported the method of allocation con-
cealment. Four reported blinded outcome assessment but failed
to describe the method. One assessed the effect of antifibrinolyt-
ics on mortality, but no deaths occurred. Five reported the effects
on blood loss but only one had sufficient data to enable the cal-
culation of the effect estimate and confidence intervals. One
reported a decrease in gastric bleeding of 0.09 ml (95%
confidence interval 0.08 to 0.10). One reported a decrease in
blood loss by an average of 523 ml but failed to give the standard
deviation. One reported a decrease in blood loss by 0.83 ml but
did not give the number of animals in the control group, so the
confidence interval could not be calculated.
Thrombolysis in acute ischaemic stroke
Thrombolysis with recombinant tissue plasminogen activator
reduces death or dependency after ischaemic stroke, despite an
increase in intracranial haemorrhage.13 14 Overall, 113 reports
were found on the effects of using tissue plasminogen activator
or related agents for thrombolysis in animal models of acute
ischaemic stroke (369 comparisons).w26-w138 The quality of the
experiments was poor (table 1). Infarct volume was reported in
212 comparisons (3301 animals), neurobehavioural scores in 84
(1438 animals), and haemorrhage in 146 (2791 animals). The
funnel plot suggested an excess of imprecise studies overstating
efficacy (fig 2) and this was supported by an Egger regression
analysis (P < 0.001). Tissue plasminogen activator reduced
infarct volume by 24% (95% confidence interval 20% to 28%),
improved neurobehavioural scores by 23% (17% to 29%), and
increased the probability of haemorrhage (odds ratio 1.96, 95%
confidence interval 1.63 to 2.35; fig 3). Substantial heterogeneity
was found for infarct volume (I2 = 78.2%, P < 0.0001) and for
neurobehavioural scores (I2 = 75.2%, P < 0.0001) but not for
haemorrhage (I2 = 0%).
Tirilazad in acute ischaemic stroke
Tirilazad increases the risk of death and dependency in patients
with acute ischaemic stoke.15 Eighteen reports were found of
tirilazad in animal models of acute ischaemic stroke (34
Quality of animal studies. Values are numbers (percentages)
Intervention (No of studies)
Random
allocation to
group
Adequate
allocation
concealment
Blinded
assessment
of outcome
Corticosteroids for traumatic head injury
(n=17)
2 (12) 3 (18) 3 (18)
Antifibrinolytic agents (n=8) 3 (38) 0 4 (50)
Thrombolysis for acute ischaemic stroke
(n=113)
43 (38) 23 (20) 24 (21)
Tirilazad for acute ischaemic stroke (n=18) 12 (67) 1 (6) 13 (72)
Antenatal corticosteroids (n=56) 14 (25) 0 3 (5)
*Bisphosphonates (n=16) 5 (31) 0 0
*In accordance with definition by Schulz et al.
Hall 1985w6
Hall et al 1987w7
Hall and Yonkers 1989w9
Hall and Yonkers 1989w9
Overall
0.2 1 5
Study
0.73 (0.39 to 1.36)
0.82 (0.23 to 2.85)
0.48 (0.20 to 1.14)
0.49 (0.29 to 0.85)
0.58 (0.41 to 0.83)
Odds ratio (95% CI)
29.0
6.8
18.7
45.5
100.0
Weight (%)Odds ratio
Favours
treatment
Favours
control
Fig 1 Meta-analysis showing effects of corticosteroids on ability of mice to
remain on a taut string (grip test)
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comparisons).w139-w156 All 18 reports presented infarct volumes
and eight reported neurobehavioural outcomes (fig 4). The qual-
ity of the experiments was poor (table 1). The funnel plot
suggested a preponderance of small experiments overstating
efficacy but this was not supported by an Egger regression analy-
sis. Tirilazad reduced infarct volume by 29% (95% confidence
interval 21% to 37%) and improved neurobehavioural scores by
48% (29% to 67%). Substantial heterogeneity was found for both
outcome measures (infarct volume I2 = 73.3%, P < 0.0001:
neurobehavioural scores I2 = 58.1%, P < 0.002).
Antenatal corticosteroids to prevent neonatal respiratory
distress syndrome
Antenatal corticosteroids reduce respiratory distress syndrome
and mortality in neonates.16 In total, 56 reports were found of
corticosteroids in animal models of preterm delivery (56
comparisons).w157-w212 Thirty two assessed intramuscular or subcu-
taneous injections in mothers, six assessed intraperitoneal instil-
lation in mothers, and 18 assessed direct injections into the fetus.
Only three assessed the effect of maternal corticosteroid
injections on respiratory distress syndrome in the neonates (one
each in monkeys, cattle, and rabbits). Respiratory distress
syndrome was measured differently in the three studies. The
quality of the experiments was poor (table 1).
Respiratory distress syndrome was reduced in the corticos-
teroid groups in all three experiments. In one experiment two of
15 calves in the corticosteroid group compared with nine in the
control group developed respiratory distress syndrome
(P = 0.01). In another experiment the total (SD) lung capacity in
newborn rabbits in the corticosteroid group was 1.8 (0.4) ml/g
compared with 1.4 (0.4) ml/g in the control group. In a third
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Fig 2 Funnel plot showing effects of thrombolysis using recombinant tissue
plasminogen activator or related agents in animal models of acute ischaemic
stroke
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Fig 3 Effects of thrombolysis using recombinant tissue plasminogen activator
or related agents in animal models of acute ischaemic stroke. Comparisons are
ranked according to effect on infarct volume, neurobehavioural scores, and odds
of haemorrhage. Grey bars are 95% confidence limits of global estimate of
efficacy. Vertical error bars are 95% confidence limits for individual estimates
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Fig 4 Effect of tirilazad in animal models of acute ischaemic stroke.
Comparisons ranked according to effect on infarct volume or neurobehavioural
scores. Grey bars are 95% confidence limits of global estimates of efficacy.
Vertical error bars are 95% confidence limits for individual estimates
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experiment, six of 12 monkeys in the corticosteroid treated
group compared with 11 in the control group developed severe
respiratory distress syndrome (P = 0.03). Seven experiments
reported the effects of corticosteroids on neonatal mortality:
pooled odds ratio for mortality 4.2 (95% confidence interval 0.85
to 20.9). Significant heterogeneity was found (I2 = 72.7%,
P = 0.003). The pooled odds ratio for mortality in ewe models
was 12.5 (1.9 to 79.2) with no evidence of significant heterogene-
ity (I2 = 33.1%, P = 0.22).
Bisphosphonates to treat osteoporosis
Bisphosphonates increase bone mineral density in postmeno-
pausal women with osteoporosis.17 Sixteen reports were found of
bisphosphonates in animal models (two experiments in baboons
and 14 in rats).w213-w228 The quality of the experiments was poor
(table 1). All experiments were carried out in ovariectomised ani-
mals. The effect of bisphosphonates on bone mineral density was
reported in 11 experiments (fig 5). When outcome data were
available, 11 of 11 (100%) studies showed an increase in bone
mineral density and six of six (100%) studies showed
improvements in bone mass.
Meta-analysis showed that compared with placebo alendro-
nate increased bone mineral density by 11.0% (95% confidence
interval 9.2% to 12.9%) in the combined results for the hip
region. The corresponding treatment effect in the lumbar spine
was 8.5% (5.8% to 11.2%) and in the combined results for the
forearms (baboons only) was 1.7% ( − 1.4% to 4.7%).
Discussion
Concordance between animal studies and clinical studies varied
for six interventions: three had similar outcomes and three did
not. Thrombolysis with tissue plasminogen activator was effective
in animal models of acute ischaemic stroke and the results
agreed with the clinical trials. The animal studies were of poor
quality, however, with evidence of publication bias. Our evidence
for concordance may therefore be biased. We found over 100
experiments, totalling more than 3000 animals. The pooled
result was therefore precise although not necessarily valid. The
concordance may be explained by the large volume of evidence
and the replication of similar designs in different animals and
different laboratories. Furthermore, tissue plasminogen activator
was tested in older animals, in those with comorbidities, and at a
range of intervals after stroke onset, ensuring a reasonable match
with patients in clinical trials. The results for bisphosphonates to
treat osteoporosis agreed between animal studies and clinical tri-
als. We also found that antenatal corticosteroids reduced neona-
tal respiratory distress syndrome in animal studies and in clinical
trials, although the data were sparse and we found no evidence of
agreement for mortality.
The four experiments in our meta-analysis of corticosteroids
in animal head injury models used the weight drop model.28 All
had good allocation concealment and blinded outcome
assessment. Taken together they showed benefit. The experi-
ments were, however, from one laboratory, had little evidence on
adverse effects, and did not examine the influence of comorbidi-
ties. We also found a difference in results for tirilazad to treat
stroke. The data from the animal studies suggested a benefit but
the clinical trials showed no benefit and possible harm. It should
be noted that the interval between stroke onset and treatment
was longer in the clinical studies (median five hours) than in the
animal models (median 10 minutes). Some of the clinical trials
recruited patients up to 24 hours after stroke onset. For antifibri-
nolytics in haemorrhage, clinical trials showed clear evidence of
benefit despite the lack of any reliable data from animal models.
Methodological strengths and weaknesses
It would be inappropriate to make general statements about the
utility of animal research on the basis of only six interventions.
Animal studies are often carried out to learn about biological
mechanisms and we cannot comment on the value of animal
research in these areas nor provide precise estimates of
agreement. Although we tried to contact the authors of
individual animal studies, we analysed what was reported and
cannot rule out that other relevant data were not published. Our
systematic review does, however, provide insights into the limita-
tions of animal models, including the extent to which they repre-
sent disease in humans. As the number of systematic reviews of
animal experiments increases, a quantitative approach to deter-
mine similarities between animal models and clinical trials
should be possible in the future.
Implications for research
Systematic reviews could facilitate the translation of research
findings from animals to humans. The animal studies in our sys-
tematic review varied in methodological quality and sample sizes
rather than providing a single definitive high quality experiment
for each intervention. Randomisation and blinding were rarely
reported, which can have important implications as it has been
shown that animal experiments carried out without either are
five times more likely to report a positive treatment effect.23 In
the systematic review of thrombolysis in acute ischaemic stroke
we found strong evidence of publication bias. The number of
experiments in the other systematic reviews made assessment of
this source of bias difficult. In most cases we pooled the results to
provide precise estimates of efficacy, although given the extent of
heterogeneity the precision is open to question. These methodo-
logical issues are important given concerns about the differences
between promising animal studies and negative clinical trials
across a range of interventions. Because animal experiments are
part of the evidence used to decide which interventions are taken
forward in clinical trials, efforts to avoid bias and random error
are as important when reviewing the results of animal models as
when reviewing the results of clinical trials.
Prospective registration of animal experiments might reduce
publication bias. Although the agencies that regulate animal
research hold records of animal studies we were unable to access
these. Animal research in the United Kingdom is regulated by
the Home Office. We asked the Home Office for details of any
animal experiments relevant to our study but they were unable to
provide them. In response they stated: “It is not Home Office
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Fig 5 Point estimates and 95% confidence intervals for change in bone mineral
density after alendronate administration in baboons, rats, and all animals
combined compared with results from clinical trials
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policy or practice to gather or retain information derived from
work licensed under the Animals (Scientific Procedures) Act
1986 in the way you envisage. Such information is, generally,
held by the licensed establishments concerned and made
available to Home Office inspectors for inspection on site,
should the need arise. I am, therefore, unable to provide you with
any of the information you request. Nor am I able to confirm
from Home Office records that any relevant trials were
conducted under projects licensed under the 1986 act.” We did
not invoke the Freedom of Information Act. Nevertheless, the
Home Office response calls into question the usefulness of its
records in relation to efforts to create an accessible register of
animal experiments.
Research is needed on the aspects of study design that can
bias treatment effects in animal models. Empirical evidence of
bias from study design characteristics helped to improve the
quality of clinical trials and might do the same for animal experi-
ments. Standards for evidence based reporting, similar to the
consolidated standards of reporting trials statement for clinical
trials, might ensure that relevant aspects of experiment method-
ology are reported.29
Systematic reviews can provide insights into the limitations of
animal models. For example, the animal models for stroke, where
there was agreement with the results from clinical trials, seemed
more representative of the condition in humans than the animal
models for head injury, where there were differences in the
results. In stroke, the time from the occlusive event to the start of
treatment was similar in animal and human studies. In head
injury, treatment was given within five minutes of injury in the
animal models but up to eight hours after injury in the clinical
trials. None of the animal experiments used models that mimic
the complex situations that usually follow traumatic head injury.
Comorbidities are clearly relevant in stroke, which occurs in
older people with hypertension and diabetes but also in people
with head injuries, often accompanied by other injuries and by
hypotension and hypothermia. Comorbidities were examined in
the stroke models but not in the head injury models.
That there is a gap between clinical research and clinical
practice is well established.30 Our work highlights another gap—
specifically the lack of communication between those involved in
animal research and clinical trialists. Systematic reviews of
animal experiments could promote closer collaboration between
the research communities and encourage an iterative approach
to improving the relevance of animal models to clinical trial
design. When models do not represent the clinical context they
could be adapted accordingly. Furthermore, as is the case for
human research, systematic reviews could help identify and
improve deficiencies in the conduct and reporting of animal
research.
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